vTv Therapeutics to Participate in Upcoming Investor Conferences
Oppenheimer 36th Annual
Date: Thursday, February 26, 2026
Time:
Format: Presentation Only
Location: Virtual
Webcast Link
Date: Tuesday, March 3, 2026
Time:
Format: Presentation and 1x1 Meetings
Location:
Webcast Link
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Investor Contact
jfraunces@lifesciadvisors.com
Media Contact
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
Source: vTv Therapeutics Inc.